Joseph L. Witztum
Scripps Research Institute
34 Papers
707 Citations
Joseph L. Witztum is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Apolipoprotein B & Low-density lipoprotein. The author has an hindex of 20, co-authored 34 publications. Previous affiliations of Joseph L. Witztum include University of California, San Francisco.
Chat about Author
Papers
Probucol inhibits oxidative modification of low density lipoprotein.
TL;DR: The findings suggest the hypothetical but intriguing possibility that probucol, in addition to its recognized effects on plasma LDL levels, may inhibit atherogenesis by limiting oxidative LDL modification and thus foam cell formation and/or EC injury.
Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism.
TL;DR: These studies demonstrate that all of the changes associated with endothelial cell modification of LDL can be attributed to oxidation, and the cells can, however, promote oxidation under conditions where it would otherwise occur very slowly.
487
The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis.
TL;DR: Inhibition of the oxidation of LDL may be another approach to inhibiting atherogenesis, additive to or even synergistic with lowering of plasma LDL levels.
410
Increased Autoantibody Titers Against Epitopes of Oxidized LDL in LDL Receptor–Deficient Mice With Increased Atherosclerosis
TL;DR: The results suggest that the rise in autoantibody titers to an epitope of Ox-LDL in this murine model is partially determined by the extent of atherosclerosis but could also be influenced by the degree of hypercholesterolemia or other factors that may influence lipid peroxidation.